Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
Recruiting · NCT07083154 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) | Cognition Disorders, Cognitive Dysfunction, Hemic and Lymphatic Diseases, Mild Cognitive Impairment, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, cognitive disorder, dementia, diabetes mellitus, endocrine system disorder, follicular lymphoma, glucose metabolism disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, metabolic disease, neoplasm, nervous system disorder, psychiatric disorder, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-02 | NCT07083154 |
8 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.